%0 Journal Article %A Komal Shah %A Nupur Desai %A Dileep Mavalankar %T Secondary Attack Rate (SAR) in household contacts of expired primary cases of COVID-19: A study from Western India %D 2020 %R 10.1101/2020.11.17.20231290 %J medRxiv %P 2020.11.17.20231290 %X Secondary attack rate (SAR) in household contacts of expired primary COVID-19 cases is not well studied yet. Based on our previous pilot study conducted in Gandhinagar district of Gujarat state, we developed a new research protocol to understand SAR statistics in household contacts of COVID-19 cases that died/expired. The details of expired COVID positive primary cases were obtained from Government records and the details of secondary cases were retrieved using telephonic interviews of the household members. Forty-nine expired cases were registered between March to August, 2020. Out of 49 deaths, 28 families could be reached on phone. Rest were not reachable or refused to give information. These were interviewed after taking verbal consent. The study reported 25% SAR in household contact of expired primary cases with 7.4% of mortality in secondary cases. Though this is representative data only from a single district, it was observed that 75% of the household contacts were still not infected in spite of repeated contact with the sever cases. More such studies in various regions are needed to understand disease transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Ethics Committee, Indian Institute of Public Health Gandhinagar has reviewed and approved the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe will be available on request. %U https://www.medrxiv.org/content/medrxiv/early/2020/11/20/2020.11.17.20231290.full.pdf